How Tesamorelin is Administered
Tesamorelin is administered as a 2 mg subcutaneous injection once daily 1, 2, 3, 4.
Administration Details
Dosing and Route
- Standard dose: 2 mg subcutaneously once daily 2, 3, 4
- Route: Subcutaneous injection only
- Timing: Administered daily, typically at the same time each day for consistency
Injection Technique
The medication is given as a subcutaneous injection, which means it is injected into the fatty tissue layer between the skin and muscle. Based on the clinical trial data, patients can self-administer these injections after proper training 2, 3.
Duration of Treatment
Clinical trials have demonstrated efficacy and safety for:
- Initial treatment period: 26 weeks (6 months) 3
- Extended treatment: Up to 52 weeks (12 months) with maintained benefits 2, 3, 4
- Continuous daily dosing is required to maintain therapeutic effects, as discontinuation leads to reversal of benefits 3
Important Administration Considerations
Treatment Continuity
Do not exceed 7 days of missed doses 1. The medication requires consistent daily administration to maintain its effects on visceral adipose tissue reduction. When tesamorelin was discontinued in clinical trials (T-P group), the beneficial effects on visceral fat were lost 3.
Injection Site Management
Common injection-site reactions include erythema and local discomfort 5. Rotating injection sites can help minimize these effects, though specific rotation protocols were not detailed in the evidence.
Monitoring During Treatment
While administering tesamorelin:
- Glucose parameters should be monitored, particularly in the first 2 weeks when transient increases in fasting glucose may occur 2
- IGF-1 levels increase significantly (mean increase of 108 ng/ml) and can be used to confirm biological response 3
- Clinical response is typically assessed at 26 weeks, with body composition changes (visceral fat, waist circumference) serving as primary efficacy markers 2, 3